CJC-1295 with DAC

Lyochem buyer fit

Overview

Belonging to the Modified GRF 1-29 family, CJC-1295 with DAC achieves its extended duration through a maleimido-propionyl group installed at Lys30, which reacts covalently with Cys34 on circulating serum albumin, the Drug Affinity Complex (DAC) principle. Anchoring to albumin stretches the plasma half-life from the roughly 30 minutes of the no-DAC peptide out to approximately 6-8 days, which is what enables once-weekly regimens in research and compounding settings. Lyochem supplies CJC-1295 with DAC as the lyophilized acetate reference standard at ≥99.0% HPLC. This variant demands stricter identity work than the no-DAC form, because a partially hydrolyzed maleimide co-elutes at the same retention time and clears the standard purity gate while having lost its albumin-conjugating capacity, so the modification must be verified intact at the labeled position. Release therefore combines peak-integration HPLC with ESI-MS confirming the modified mass; a thiol-reactivity assay can be added when the buyer’s written analytical scope requires maleimide-integrity evidence. The prolonged exposure profile favors sustained-elevation GH studies, whereas pulse-pharmacology work that must preserve native secretory architecture is better served by the no-DAC form.

Applications & buyer fit

Specifications

CAS

863288-34-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 5.8-8.1 days

MOQ

On request

Lead time

10–18 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion analysis (acetate vs TFA)
• Stability at −20 °C across 12 months
• Solubility in BAC water / PBS reconstitution

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.

Selected literature

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
4. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.

Frequently asked questions